DBV Technologies ADR Dossier - Source-backed chat

DBV Technologies ADR

DBVEuronext Paris

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.18

Intrinsic Value $3.28median of 2 methodsbased on filings through 30 Jun 2026

Market Price $11.21Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 71% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-71%)

Data confidence Sign in to view data confidence

Market Cap $704.5M

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

DBV Technologies is a late-stage clinical biopharmaceutical company transitioning toward commercial readiness with its proprietary epicutaneous immunotherapy (EPIT) platform, led by the Viaskin Peanut patch. Following positive Phase III VITESSE trial results in children aged 4-7, the company is on track to submit its Biologics License Application (BLA) to the FDA in Q3 2026. Although the BLA filing was slightly delayed from H1 2026 to address FDA feedback on CMC and biostatistical data formatting, the delay is non-data-related, preserving the therapeutic's strong clinical profile. Backed by a robust cash position of $174.9 million as of June 30, 2026, which provides an operational runway into Q3 2027, DBV Technologies represents a highly attractive high-upside opportunity in the food allergy space, offering a non-invasive alternative to oral immunotherapies.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.79

Mean target$40.59

High · most bullish analyst$54.71

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.7920%

The FDA issues a Complete Response Letter (CRL) or requests additional clinical trials due to CMC or manufacturing compliance issues, pushing approval timelines past 2028. The cash runway is depleted faster than expected, forcing highly dilutive equity raises or unfavorable licensing deals. Commercial uptake is slow due to high pricing or restrictive payer coverage.

Base CaseCentral scenario

$40.5950%

Matches the consensus mean

The BLA for Viaskin Peanut in children aged 4-7 is submitted in Q3 2026 and accepted by the FDA. Standard review proceeds with potential approval in mid-to-late 2027. Commercial launch preparations continue with moderate cash burn, supported by existing cash reserves and selective ATM utilization. Toddler BLA submission proceeds in H1 2027 following full analysis of the COMFORT Toddlers study.

Bull CaseUpside scenario

$54.7130%

The FDA accepts and grants standard 10-month review to the Viaskin Peanut BLA in late 2026, leading to approval and commercial launch in late 2027. Rapid market adoption occurs due to strong clinical preference for a non-invasive patch over oral immunotherapy (such as Palforzia). The toddler (ages 1-3) BLA is submitted in late 2026/early 2027, expanding the addressable market. The company successfully utilizes its refreshed $150 million ATM program to fund commercial launch activities without severe dilution.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated non-invasive epicutaneous immunotherapy (EPIT) platform with no direct patch-based competitors.
Positive Phase III VITESSE trial results meeting primary endpoints with a strong safety and tolerability profile.
Substantial cash runway of $174.9 million as of June 30, 2026, funding operations into Q3 2027.
Completed recruitment for the COMFORT Toddlers supplemental safety study, paving the way for a second pediatric indication.

Key Investment Risks

Regulatory execution risk, including potential further delays in BLA submission or FDA review.
Commercial adoption risk, given the historically slow market uptake of oral immunotherapy alternatives like Palforzia.
High cash burn rate typical of pre-commercial biotech companies, leading to potential future shareholder dilution.

Thesis Invalidation Triggers

FDA refusal to file or accept the BLA submission in Q3 2026.
Unexpected safety signals or negative findings from the COMFORT Toddlers study or VITESSE Open-Label Extension.
Severe cash depletion leading to a going-concern warning before the mid-2027 runway target.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.